Athira Pharma, Inc.
ATHA
$0.36
$0.01885.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.23M | 6.20M | 7.57M | 5.87M | 6.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.54M | 15.57M | 25.49M | 28.03M | 27.69M |
| Operating Income | -9.54M | -15.57M | -25.49M | -28.03M | -27.69M |
| Income Before Tax | -9.14M | -15.00M | -28.74M | -26.86M | -26.34M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.14M | -15.00M | -28.74M | -26.86M | -26.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.14M | -15.00M | -28.74M | -26.86M | -26.34M |
| EBIT | -9.54M | -15.57M | -25.49M | -28.03M | -27.69M |
| EBITDA | -9.29M | -15.32M | -25.25M | -27.79M | -27.45M |
| EPS Basic | -0.23 | -0.39 | -0.75 | -0.70 | -0.69 |
| Normalized Basic EPS | -0.15 | -0.24 | -0.40 | -0.44 | -0.43 |
| EPS Diluted | -0.23 | -0.39 | -0.75 | -0.70 | -0.69 |
| Normalized Diluted EPS | -0.15 | -0.24 | -0.40 | -0.44 | -0.43 |
| Average Basic Shares Outstanding | 39.04M | 38.70M | 38.52M | 38.38M | 38.32M |
| Average Diluted Shares Outstanding | 39.04M | 38.70M | 38.52M | 38.38M | 38.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |